Summary Type 1 diabetes (T1D) is widely considered to result from the autoimmune
destruction of insulin-producing β cells. This concept has been a central tenet for decades of …

We review the current knowledge of pancreas pathology in type 1 diabetes. During the last
two decades, dedicated efforts toward the recovery of pancreas from deceased patients with …

Oral administration is the preferred route of administration based on the convenience for and
compliance of the patient. Oral nanomedicines have been developed to overcome the …

Immune checkpoint inhibitors have transformed the landscape of oncological therapy, but at
the price of a new array of immune related adverse events. Among these is β-cell failure …

BACKGROUND Checkpoint inhibitor–associated autoimmune diabetes mellitus (CIADM) is
a distinct form of autoimmune diabetes that is a rare complication of immune checkpoint …

The proportions and phenotypes of immune cell subsets in peripheral blood undergo
continual and dramatic remodeling throughout the human life span, which complicates …

Context Individuals with type 1 diabetes (T1D) have a smaller pancreas, but longitudinal
changes in pancreas size and shape are unclear. Objective We monitored changes in …

Recent reports have revived interest in the active role that β-cells may play in type 1
diabetes pathogenesis at different stages of disease. In some studies, investigators …

Context. Type 1 diabetes (T1D) is a heterogeneous disease affecting the islets and the
exocrine pancreas. How the topographical distribution of the involved tissue lesions …

The rubric of immune-related (ir) diabetes mellitus (DM)(irDM) encompasses various
hyperglycemic disorders related to immune checkpoint inhibitors (ICPis). Beyond sharing …